According to the Canada-United States-Mexico Agreement (CUSMA)1, Canadian patent applications filed on or after December 1, 20202, may be eligible for patent term adjustment (PTA) if they have been subjected to unreasonable prosecution delay by the Canadian Intellectual Property Office (CIPO)3. This is one of the changes resulting from the CUSMA, which entered into force on July 1, 20204.
What you need to know
- Article 20.44 of the CUSMA requires the respective granting authorities of each signing country (i.e., CIPO for applicants in Canada) to process applications “in an efficient and timely manner, with a view to avoiding unreasonable and unnecessary delays”5. If an “unreasonable delay” occurs, a patentee may request a PTA to compensate for prosecution delays6.
- CUSMA defines an “unreasonable delay” as a delay in issuance of more than five years from the date of filing or more than three years from the request for examination, whichever is later7. Certain delays may be excluded from this calculation, including delays attributable to the patent applicant8 and delays that are not directly attributable to the granting authority (i.e., CIPO)9.
- While Canada has not yet amended its patent statute to provide for PTA for unreasonable prosecution delays, it is required to do so within 4.5 years of the CUSMA entering into force (i.e., no later than January 1, 2025)10. Until the patent statute is amended, the precise details of PTA for unreasonable prosecution delays in Canada remain unknown.
Distinct from Certificates of Supplementary Protection
Note that PTAs for unreasonable prosecution delays arising from the CUSMA are distinct from previously existing extensions available in the form of Certificates of Supplementary Protection (CSP). Since September 2017, Canada has provided up to two years of sui generis patent-like protection for pharmaceutical products containing a new medicinal ingredient or a new combination of medicinal ingredients, protected by an eligible patent11. Unlike PTA for unreasonable prosecution delays, CSPs are intended to compensate for delays in obtaining regulatory approval for new drugs12. Therefore, assuming Canada amends its patent statute to introduce PTA for unreasonable prosecution delays in compliance with its obligations under the CUSMA, there will be two distinct forms of patent term extension in Canada.
1 Agreement between Canada, the United States of America and the United Mexican States, 30 November 2018, Can TS 2020 No 5 (revised 10 December 2019, entered into force 1 July 2020) [CUSMA]. Also known as the United States-Mexico-Canada Agreement (USMCA) in the United States.
2 Ibid, art 20.44.
4 CUSMA, supra note 1.
5 Ibid, art 20.44.
10 CUSMA, supra note 1, art 20.89.
11 See Torys’ bulletins: “Finalizing Patent Term Extension in Canada” for additional information on patent term extensions in the form of CSPs. Also see Torys’ bulletins: “Federal Court instructs Health Canada to reconsider “medicinal ingredient” in the context of CSP” and “Health Canada instructed to reconsider scope of CSP protection for drug containing multiple active ingredients” for two examples of where the refusal to grant a CSP was sent back for redetermination upon judicial review.
12 Note that article 20.46 of CUSMA requires its signatories also to provide PTA for pharmaceutical products subject to a patent and that have experienced “unreasonable curtailment of the effective patent term as a result of the marketing approval process.” However, Canada already meets the CUSMA obligation by way of its existing CSP regime.
To discuss these issues, please contact the author(s).
This publication is a general discussion of certain legal and related developments and should not be relied upon as legal advice. If you require legal advice, we would be pleased to discuss the issues in this publication with you, in the context of your particular circumstances.
For permission to republish this or any other publication, contact Janelle Weed.
© 2021 by Torys LLP.
All rights reserved.